Sectors & Industries HealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2026)
Top diagnostic & research stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +28.50% per year, and are the best diagnostic & research stocks to buy now. Learn More.

Industry: Diagnostics & Research

Zen Rating Price Value Growth Financials Momentum Sentiment Forecast Dividends Due Diligence

Diagnostics & Research is Zen Rated B and is the 37th ranked industry out of 145 stock market industries

Ticker	Company	Exchange	Industry	Market Cap	Price	1d %	EBITDA	P/E	D/E	Country
NEOG	NEOGEN CORP	NASDAQ	Diagnostics & Research	$2.44B	$11.19	-3.53%	$112.03M	-43.04x	0.58	United States
LH	LABCORP HOLDINGS INC	NYSE	Diagnostics & Research	$30.23B	$372.32	0.02%	$2.37B	30.34x	1.14	United States
CDNA	CAREDX INC	NASDAQ	Diagnostics & Research	$4.19B	$79.81	-1.68%	$140.05M	32.05x	0.37	United States
DGX	QUEST DIAGNOSTICS INC	NYSE	Diagnostics & Research	$28.57B	$259.65	0.37%	$2.31B	25.51x	1.22	United States
CRL	CHARLES RIVER LABORATORIES INTERNATIONAL INC	NYSE	Diagnostics & Research	$16.33B	$340.81	-0.55%	$291.74M	318.51x	1.29	United States
SHC	SOTERA HEALTH CO	NASDAQ	Diagnostics & Research	$4.66B	$16.30	-0.85%	$542.47M	27.17x	3.62	United States
CSTL	CASTLE BIOSCIENCES INC	NASDAQ	Diagnostics & Research	$1.06B	$34.50	1.50%	-$6.12M	-45.39x	0.21	United States
RVTY	REVVITY INC	NYSE	Diagnostics & Research	$17.53B	$157.02	-0.78%	$785.62M	69.79x	0.58	United States
A	AGILENT TECHNOLOGIES INC	NYSE	Diagnostics & Research	$48.78B	$173.01	-2.23%	$2.04B	33.92x	0.90	United States
DHR	DANAHER CORP	NYSE	Diagnostics & Research	$163.33B	$232.16	-1.34%	$7.85B	37.93x	0.74	United States
IQV	IQVIA HOLDINGS INC	NYSE	Diagnostics & Research	$44.68B	$271.11	-1.25%	$3.65B	32.62x	3.56	United States
NEO	NEOGENOMICS INC	NASDAQ	Diagnostics & Research	$2.14B	$16.54	-1.72%	$39.43M	-68.92x	0.72	United States
MTD	METTLER TOLEDO INTERNATIONAL INC	NYSE	Diagnostics & Research	$34.43B	$1,730.93	-1.03%	$1.33B	37.49x	46.59	United States
WAT	WATERS CORP	NYSE	Diagnostics & Research	$45.43B	$462.20	-1.85%	$1.15B	190.99x	0.58	United States
TMO	THERMO FISHER SCIENTIFIC INC	NYSE	Diagnostics & Research	$259.15B	$699.44	-2.55%	$12.46B	36.83x	1.09	United States
QGEN	QIAGEN NV	NYSE	Diagnostics & Research	$10.35B	$50.10	-0.40%	$705.36M	27.23x	0.71	Netherlands
IDXX	IDEXX LABORATORIES INC	NASDAQ	Diagnostics & Research	$54.99B	$698.02	-0.65%	$1.67B	46.78x	0.98	United States
BLLN	BILLIONTOONE INC	NASDAQ	Diagnostics & Research	$5.29B	$110.79	0.51%	$62.68M	103.54x	0.34	United States
ILMN	ILLUMINA INC	NASDAQ	Diagnostics & Research	$31.68B	$209.55	-1.59%	$1.43B	35.64x	1.17	United States
MEDP	MEDPACE HOLDINGS INC	NASDAQ	Diagnostics & Research	$18.37B	$656.84	-1.19%	$665.29M	35.81x	2.94	United States
PRPO	PRECIPIO INC	NASDAQ	Diagnostics & Research	$41.69M	$23.25	-6.25%	$800.00k	-39.41x	0.46	United States
BNR	BURNING ROCK BIOTECH LTD	NASDAQ	Diagnostics & Research	$144.77M	$13.33	0.68%	N/A	-13.76x	0.51	China
RDNT	RADNET INC	NASDAQ	Diagnostics & Research	$5.99B	$76.04	-2.61%	$312.97M	-262.21x	2.54	United States
ICLR	ICON PLC	NASDAQ	Diagnostics & Research	$15.02B	$200.51	0.41%	$1.11B	34.28x	0.78	Ireland
STIM	NEURONETICS INC	NASDAQ	Diagnostics & Research	$111.15M	$1.43	-11.73%	-$11.24M	-4.33x	5.86	United States
FLGT	FULGENT GENETICS INC	NASDAQ	Diagnostics & Research	$694.28M	$24.85	-3.31%	-$69.14M	-8.04x	0.10	United States
TWST	TWIST BIOSCIENCE CORP	NASDAQ	Diagnostics & Research	$7.16B	$114.22	-6.83%	-$110.48M	-51.45x	0.51	United States
QUCY	QUANTUM CYBER NV	NASDAQ	Diagnostics & Research	$47.41M	$0.56	-9.76%	-$22.12M	-0.50x	0.15	Germany
NTRA	NATERA INC	NASDAQ	Diagnostics & Research	$46.83B	$322.94	0.98%	-$117.96M	-285.79x	0.47	United States
GRAL	GRAIL INC	NASDAQ	Diagnostics & Research	$5.46B	$121.35	-3.41%	-$393.21M	-12.85x	0.11	United States
MYGN	MYRIAD GENETICS INC	NASDAQ	Diagnostics & Research	$544.84M	$5.68	-0.70%	-$58.00M	-4.21x	1.27	United States
OPK	OPKO HEALTH INC	NASDAQ	Diagnostics & Research	$1.24B	$1.67	-2.34%	-$45.33M	-8.79x	0.69	United States
BDSX	BIODESIX INC	NASDAQ	Diagnostics & Research	$108.56M	$9.79	-3.26%	-$13.46M	-3.63x	9.83	United States
GH	GUARDANT HEALTH INC	NASDAQ	Diagnostics & Research	$20.95B	$154.86	0.05%	-$441.45M	-42.08x	-7.83	United States
ACRS	ACLARIS THERAPEUTICS INC	NASDAQ	Diagnostics & Research	$634.45M	$4.00	-7.83%	-$79.22M	-6.90x	0.30	United States
XGN	EXAGEN INC	NASDAQ	Diagnostics & Research	$112.51M	$4.41	-12.41%	-$9.71M	-5.88x	3.02	United States
BIAF	BIOAFFINITY TECHNOLOGIES INC	NASDAQ	Diagnostics & Research	$4.26M	$2.34	-3.51%	-$14.99M	-0.05x	0.93	United States
IMDX	INSIGHT MOLECULAR DIAGNOSTICS INC	NASDAQ	Diagnostics & Research	$75.59M	$2.31	-3.35%	-$46.82M	-1.53x	-2.38	United States
FRNM	FREENOME INC	NASDAQ	Diagnostics & Research	$1.14B	$10.61	-8.22%	-$242.74M	-0.99x	-0.30	United States
TRIB	TRINITY BIOTECH PLC	NASDAQ	Diagnostics & Research	$3.67M	$5.88	1.03%	-$13.11M	-0.10x	-2.46	Ireland
NDRA	ENDRA LIFE SCIENCES INC	NASDAQ	Diagnostics & Research	$6.96M	$4.64	-2.70%	-$5.76M	-0.73x	0.26	United States
MDXH	MDXHEALTH SA	NASDAQ	Diagnostics & Research	$719.10k	$0.14	-4.11%	-$8.87M	-0.02x	-5.34	Belgium
XWEL	XWELL INC	NASDAQ	Diagnostics & Research	$4.80M	$0.56	1.27%	-$21.94M	-0.11x	-6.62	United States
MBAI	MBODY AI LTD	NASDAQ	Diagnostics & Research	$2.10M	$2.09	-4.57%	$4.15M	0.45x	1.18	Israel
VNRX	VOLITIONRX LTD	NYSEMKT	Diagnostics & Research	$2.51M	$0.18	-9.80%	-$23.33M	-0.05x	-1.30	United States
ISPC	ISPECIMEN INC	NASDAQ	Diagnostics & Research	$1.76M	$0.70	-1.69%	-$10.31M	-0.01x	3.26	United States
DRIO	DARIOHEALTH CORP	NASDAQ	Diagnostics & Research	$16.17M	$1.65	-22.35%	-$28.56M	-0.27x	0.75	Israel
PSNL	PERSONALIS INC	NASDAQ	Diagnostics & Research	$1.72B	$15.86	-0.63%	-$108.90M	-13.56x	0.37	United States
ADVB	ADVANCED BIOMED INC	NASDAQ	Diagnostics & Research	$5.47M	$3.31	42.67%	$6.68M	0.62x	0.12	United States
SERA	SERA PROGNOSTICS INC	NASDAQ	Diagnostics & Research	$78.74M	$1.98	2.06%	-$32.37M	-2.96x	0.53	United States

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Nov 2026?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best diagnostic & research stocks to buy right now are:

1. Neogen (NASDAQ:NEOG)

Neogen (NASDAQ:NEOG) is the #1 top diagnostic & research stock out of 50 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Neogen (NASDAQ:NEOG) is: Value: C, Growth: A, Momentum: B, Sentiment: B, Safety: C, Financials: C, and AI: C.

Neogen (NASDAQ:NEOG) has a Due Diligence Score of 13, which is -16 points lower than the diagnostic & research industry average of 29. Although this number is below the industry average, our proven quant model rates NEOG as a "A".

NEOG passed 4 out of 33 due diligence checks and has weak fundamentals. Neogen has seen its stock return 72.95% over the past year, overperforming other diagnostic & research stocks by 51 percentage points.

Neogen has an average 1 year price target of $14.00, an upside of 25.11% from Neogen's current stock price of $11.19.

Neogen stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Neogen, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Labcorp Holdings (NYSE:LH)

Labcorp Holdings (NYSE:LH) is the #2 top diagnostic & research stock out of 50 with a Zen Rating of B. Stocks with a rating of B have had an average return of +17.17% per year. Learn more.

The Component Grade breakdown for Labcorp Holdings (NYSE:LH) is: Value: C, Growth: B, Momentum: B, Sentiment: C, Safety: A, Financials: C, and AI: C.

Labcorp Holdings (NYSE:LH) has a Due Diligence Score of 38, which is 9 points higher than the diagnostic & research industry average of 29.

LH passed 14 out of 38 due diligence checks and has average fundamentals. Labcorp Holdings has seen its stock return 39.97% over the past year, overperforming other diagnostic & research stocks by 18 percentage points.

Labcorp Holdings has an average 1 year price target of $359.78, a downside of -3.37% from Labcorp Holdings's current stock price of $372.32.

Labcorp Holdings stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 9 analysts covering Labcorp Holdings, 55.56% have issued a Strong Buy rating, 11.11% have issued a Buy, 33.33% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Caredx (NASDAQ:CDNA)

Caredx (NASDAQ:CDNA) is the #3 top diagnostic & research stock out of 50 with a Zen Rating of B. Stocks with a rating of B have had an average return of +17.17% per year. Learn more.

The Component Grade breakdown for Caredx (NASDAQ:CDNA) is: Value: C, Growth: B, Momentum: A, Sentiment: A, Safety: C, Financials: C, and AI: D.

Caredx (NASDAQ:CDNA) has a Due Diligence Score of 53, which is 24 points higher than the diagnostic & research industry average of 29.

CDNA passed 18 out of 33 due diligence checks and has strong fundamentals. Caredx has seen its stock return 389.33% over the past year, overperforming other diagnostic & research stocks by 367 percentage points.

Caredx has an average 1 year price target of $79.50, a downside of -0.39% from Caredx's current stock price of $79.81.

Caredx stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Caredx, 75% have issued a Strong Buy rating, 0% have issued a Buy, 25% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 7 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Qiagen Nv (NYSE:QGEN)

Qiagen Nv (NYSE:QGEN) has an annual dividend yield of 4.57%, which is 3 percentage points higher than the diagnostic & research industry average of 1.19%.

Qiagen Nv's dividend payout ratio of 255.5% indicates that its high dividend yield might not be sustainable for the long-term.

2. Quest Diagnostics (NYSE:DGX)

Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 1.3%, which is the same as the diagnostic & research industry average of 1.19%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 33.2% indicates that its dividend yield is sustainable for the long-term.

3. Labcorp Holdings (NYSE:LH)

Labcorp Holdings (NYSE:LH) has an annual dividend yield of 0.77%, which is the same as the diagnostic & research industry average of 1.19%. Labcorp Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Labcorp Holdings's dividend has not shown consistent growth over the last 10 years.

Labcorp Holdings's dividend payout ratio of 23.5% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks down?

Diagnostic & research stocks were down -1.16% in the last day, and up 1.93% over the last week. Twist Bioscience was the among the top losers in the diagnostics & research industry, dropping -6.83% yesterday.

Twist Bioscience shares are trading lower after the company reported Q4 financial results. During a conference call, CFO Adam Laponis signaled a slowdown in gross margin expansion in FY27.

What are the most undervalued diagnostic & research stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued diagnostic & research stocks right now are:

1. Sotera Health Co (NASDAQ:SHC)

Sotera Health Co (NASDAQ:SHC) is the most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Sotera Health Co has a valuation score of 29, which is 16 points higher than the diagnostic & research industry average of 13. It passed 2 out of 7 valuation due diligence checks.

Sotera Health Co's stock has gained 0.31% in the past year. It has underperformed other stocks in the diagnostic & research industry by -22 percentage points.

2. Qiagen Nv (NYSE:QGEN)

Qiagen Nv (NYSE:QGEN) is the second most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Qiagen Nv has a valuation score of 43, which is 30 points higher than the diagnostic & research industry average of 13. It passed 3 out of 7 valuation due diligence checks.

Qiagen Nv's stock has gained 12.51% in the past year. It has underperformed other stocks in the diagnostic & research industry by -10 percentage points.

3. Danaher (NYSE:DHR)

Danaher (NYSE:DHR) is the third most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Danaher has a valuation score of 29, which is 16 points higher than the diagnostic & research industry average of 13. It passed 2 out of 7 valuation due diligence checks.

Danaher's stock has gained 5.82% in the past year. It has underperformed other stocks in the diagnostic & research industry by -16 percentage points.

Are diagnostic & research stocks a good buy now?

57.14% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 4.07% over the next year.

2.56% of diagnostic & research stocks have a Zen Rating of A (Strong Buy), 30.77% of diagnostic & research stocks are rated B (Buy), 56.41% are rated C (Hold), 10.26% are rated D (Sell), and 0% are rated F (Strong Sell).

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 28.15x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.